Compare Pfizer Inc (PFE) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Wells Fargo & Co — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Wells Fargo & Co trades at $83.55 (market cap $248.06B). The key difference: Wells Fargo & Co is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Wells Fargo & Co for 88 Days on average.
| PFE | WFC | |
|---|---|---|
Market Cap | $158.56B | $248.06B |
Volume | 44,138,282 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $29.02 | $96.40 |
52-Week Low | $23.67 | $73.42 |
Typical Hold Time | 158 Days | 88 Days |
Enterprise Value | $210.06B | $503.91B |
Dividend Yield | 6.18% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Wells Fargo (WFC) trades at $82.06, up 2.24% on the day, with a bearish technical signal from moving averages. The stock's valuation appears attractive with a P/E of 11.92 and P/B of 1.5, while profitability remains strong with a 25.97% net income margin. Recent news includes a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and upcoming Q3 earnings on October 13, 2026 (Benzinga, 2026-09-29).
The outlook is mixed: analyst consensus targets $99.13 (46.66% buy ratings), but recent earnings misses and a negative cash flow trend in 2025 pose risks. Upside potential hinges on execution amid Fed policy changes and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
